Systems biology in drug discovery and development.
暂无分享,去创建一个
[1] Yudong D. He,et al. Functional Discovery via a Compendium of Expression Profiles , 2000, Cell.
[2] S. Huang,et al. Shape-dependent control of cell growth, differentiation, and apoptosis: switching between attractors in cell regulatory networks. , 2000, Experimental cell research.
[3] Joshua M. Stuart,et al. A Gene-Coexpression Network for Global Discovery of Conserved Genetic Modules , 2003, Science.
[4] E. Kunkel. Systems biology in drug discovery , 2004, Nature Biotechnology.
[5] V. Thorsson,et al. Integrated Genomic and Proteomic Analyses of Gene Expression in Mammalian Cells*S , 2004, Molecular & Cellular Proteomics.
[6] E. Berg,et al. An integrative biology approach for analysis of drug action in models of human vascular inflammation , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[7] Leroy Hood,et al. The impact of systems approaches on biological problems in drug discovery , 2004, Nature Biotechnology.
[8] C. Hughes,et al. Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.
[9] S. Horvath,et al. Statistical Applications in Genetics and Molecular Biology , 2011 .
[10] E. Butcher. Can cell systems biology rescue drug discovery? , 2005, Nature Reviews Drug Discovery.
[11] E L Berg,et al. Biological complexity and drug discovery: a practical systems biology approach. , 2005, Systems biology.
[12] Eric J Kunkel,et al. Characterization of compound mechanisms and secondary activities by BioMAP analysis. , 2006, Journal of pharmacological and toxicological methods.
[13] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[14] Chris Wiggins,et al. ARACNE: An Algorithm for the Reconstruction of Gene Regulatory Networks in a Mammalian Cellular Context , 2004, BMC Bioinformatics.
[15] S. Paik. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. , 2007, The oncologist.
[16] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[17] Younghoon Kim,et al. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification , 2009, Bioinform..
[18] Pooja Mittal,et al. A novel signaling pathway impact analysis , 2009, Bioinform..
[19] Emanuel F Petricoin,et al. Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693 , 2010, BMC Genomics.
[20] Richard S. Judson,et al. Profiling Bioactivity of the ToxCast Chemical Library Using BioMAP Primary Human Cell Systems , 2009, Journal of biomolecular screening.
[21] M. Gerstein,et al. RNA-Seq: a revolutionary tool for transcriptomics , 2009, Nature Reviews Genetics.
[22] H. Boezen,et al. Genome-wide association studies: what do they teach us about asthma and chronic obstructive pulmonary disease? , 2009, Proceedings of the American Thoracic Society.
[23] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[24] D. Chan,et al. The Road from Discovery to Clinical Diagnostics: Lessons Learned from the First FDA-Cleared In Vitro Diagnostic Multivariate Index Assay of Proteomic Biomarkers , 2010, Cancer Epidemiology, Biomarkers & Prevention.
[25] Avi Ma’ayan,et al. Protein kinase target discovery from genome-wide messenger RNA expression profiling. , 2010, The Mount Sinai journal of medicine, New York.
[26] A. Hubbard,et al. Toxicogenomic profiling of chemically exposed humans in risk assessment. , 2010, Mutation research.
[27] Xiaobo Zhou,et al. Predicting enzyme targets for cancer drugs by profiling human Metabolic reactions in NCI-60 cell lines , 2010, BMC Bioinformatics.
[28] Joel Dudley,et al. Network-Based Elucidation of Human Disease Similarities Reveals Common Functional Modules Enriched for Pluripotent Drug Targets , 2010, PLoS Comput. Biol..
[29] Sean Ekins,et al. Chemical target and pathway toxicity mechanisms defined in primary human cell systems. , 2010, Journal of pharmacological and toxicological methods.
[30] Hans-Werner Mewes,et al. CORUM: the comprehensive resource of mammalian protein complexes , 2007, Nucleic Acids Res..
[31] O. Elemento,et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. , 2010, Blood.
[32] M. Imieliński,et al. In Situ Proteomic Analysis of Human Breast Cancer Epithelial Cells Using Laser Capture Microdissection: Annotation by Protein Set Enrichment Analysis and Gene Ontology* , 2010, Molecular & Cellular Proteomics.
[33] David Haussler,et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM , 2010, Bioinform..
[34] J. Weinstein,et al. mRNA and microRNA Expression Profiles of the NCI-60 Integrated with Drug Activities , 2010, Molecular Cancer Therapeutics.
[35] Alejandra C. Ventura,et al. Multisite Phosphorylation Provides an Effective and Flexible Mechanism for Switch-Like Protein Degradation , 2010, PloS one.
[36] Craig D Wenger,et al. Phosphoproteomics for the masses. , 2010, ACS chemical biology.
[37] P. Sharp,et al. MicroRNA functions in stress responses. , 2010, Molecular cell.
[38] A. Barabasi,et al. Network medicine : a network-based approach to human disease , 2010 .
[39] Andrew P. Feinberg,et al. Epigenomics Reveals a Functional Genome Anatomy and a New Approach to Common Disease , 2010, Nature Biotechnology.
[40] Pankaj Agarwal,et al. Systematic Drug Repositioning Based on Clinical Side-Effects , 2011, PloS one.
[41] Jennifer Park,et al. A computable cellular stress network model for non-diseased pulmonary and cardiovascular tissue , 2011, BMC Systems Biology.
[42] F. Azuaje,et al. Drug-target network in myocardial infarction reveals multiple side effects of unrelated drugs , 2011, Scientific reports.
[43] F. Prinz,et al. Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.
[44] Paul Bowness,et al. Discovery of Candidate Serum Proteomic and Metabolomic Biomarkers in Ankylosing Spondylitis* , 2011, Molecular & Cellular Proteomics.
[45] G. Daley,et al. Induced pluripotent stem cells for modelling human diseases , 2011, Philosophical Transactions of the Royal Society B: Biological Sciences.
[46] Chuan He,et al. Tet Proteins Can Convert 5-Methylcytosine to 5-Formylcytosine and 5-Carboxylcytosine , 2011, Science.
[47] Joshua M. Stuart,et al. Identification of aberrant pathway and network activity from high-throughput data. , 2011, Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing.
[48] Canguo Zhao,et al. Expression-Based In Silico Screening of Candidate Therapeutic Compounds for Lung Adenocarcinoma , 2011, PloS one.
[49] Allegra Via,et al. Phospho.ELM: a database of phosphorylation sites—update 2008 , 2007, Nucleic Acids Res..
[50] Cengizhan Ozturk,et al. Pathway analysis of high-throughput biological data within a Bayesian network framework , 2011, Bioinform..
[51] Ana Kozomara,et al. miRBase: integrating microRNA annotation and deep-sequencing data , 2010, Nucleic Acids Res..
[52] D. Cutler,et al. Genistein cooperates with the histone deacetylase inhibitor vorinostat to induce cell death in prostate cancer cells , 2012, BMC Cancer.
[53] J. Cuzick,et al. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] Sean C. Bendall,et al. Single-Cell Mass Cytometry of Differential Immune and Drug Responses Across a Human Hematopoietic Continuum , 2011, Science.
[55] Fuchu He,et al. A Systems Biology-Based Classifier for Hepatocellular Carcinoma Diagnosis , 2011, PloS one.
[56] John W Haycock,et al. 3D cell culture: a review of current approaches and techniques. , 2011, Methods in molecular biology.
[57] Teresa M. Przytycka,et al. Identifying Causal Genes and Dysregulated Pathways in Complex Diseases , 2011, PLoS Comput. Biol..
[58] F. Staedtler,et al. Integrated Epigenetics of Human Breast Cancer: Synoptic Investigation of Targeted Genes, MicroRNAs and Proteins upon Demethylation Treatment , 2011, PloS one.
[59] F. Pammolli,et al. The productivity crisis in pharmaceutical R&D , 2011, Nature Reviews Drug Discovery.
[60] D. Swinney,et al. How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.
[61] Julio Saez-Rodriguez,et al. Training Signaling Pathway Maps to Biochemical Data with Constrained Fuzzy Logic: Quantitative Analysis of Liver Cell Responses to Inflammatory Stimuli , 2011, PLoS Comput. Biol..
[62] S. Turner,et al. Going beyond five bases in DNA sequencing. , 2012, Current opinion in structural biology.
[63] Jason H. Moore,et al. Chapter 11: Genome-Wide Association Studies , 2012, PLoS Comput. Biol..
[64] Edwin K Silverman,et al. Network medicine approaches to the genetics of complex diseases. , 2012, Discovery medicine.
[65] A. Bordbar,et al. Using the reconstructed genome‐scale human metabolic network to study physiology and pathology , 2012, Journal of internal medicine.
[66] Shahab Asgharzadeh,et al. TARGETgene: A Tool for Identification of Potential Therapeutic Targets in Cancer , 2012, PloS one.
[67] Rondi A. Butler,et al. Peripheral blood DNA methylation profiles are indicative of head and neck squamous cell carcinoma: An epigenome-wide association study , 2012, Epigenetics.
[68] R. Aebersold,et al. Mass spectrometry-based proteomics and network biology. , 2012, Annual review of biochemistry.
[69] Deepak K Rajpal,et al. Applications of Connectivity Map in drug discovery and development. , 2012, Drug discovery today.
[70] Long Gao,et al. Multi-Analyte Network Markers for Tumor Prognosis , 2012, PloS one.
[71] Courtney Corley,et al. Topological analysis of protein co-abundance networks identifies novel host targets important for HCV infection and pathogenesis , 2012, BMC Systems Biology.
[72] Katsuhiko Murakami,et al. PCDq: human protein complex database with quality index which summarizes different levels of evidences of protein complexes predicted from H-Invitational protein-protein interactions integrative dataset , 2012, BMC Systems Biology.
[73] Yuanhua Liu,et al. Multilevel omic data integration in cancer cell lines: advanced annotation and emergent properties , 2013, BMC Systems Biology.
[74] Glyn Stacey,et al. Current developments in cell culture technology. , 2012, Advances in experimental medicine and biology.
[75] S. Volinia,et al. MicroRNA Expression Signatures in Solid Malignancies , 2012, Cancer journal.
[76] Susumu Goto,et al. KEGG for integration and interpretation of large-scale molecular data sets , 2011, Nucleic Acids Res..
[77] Thomas Lengauer,et al. Comparative genome-wide DNA methylation analysis of colorectal tumor and matched normal tissues , 2012, Epigenetics.
[78] Yoshihiro Yamanishi,et al. Relating drug–protein interaction network with drug side effects , 2012, Bioinform..
[79] P. Visscher,et al. Five years of GWAS discovery. , 2012, American journal of human genetics.
[80] Bin Zhang,et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse , 2011, Nucleic Acids Res..
[81] Kenny Q. Ye,et al. An integrated map of genetic variation from 1,092 human genomes , 2012, Nature.
[82] Aldert H Piersma,et al. Next-generation text-mining mediated generation of chemical response-specific gene sets for interpretation of gene expression data , 2013, BMC Medical Genomics.
[83] Claudio Altafini,et al. Predicting and characterizing selective multiple drug treatments for metabolic diseases and cancer , 2012, BMC Systems Biology.
[84] R. Tibshirani,et al. Coronary risk assessment among intermediate risk patients using a clinical and biomarker based algorithm developed and validated in two population cohorts , 2012, Current medical research and opinion.
[85] Tyler J Moss,et al. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells , 2012, Molecular systems biology.
[86] Xing-Ming Zhao,et al. Exploring drug combinations in genetic interaction network , 2012, BMC Bioinformatics.
[87] Carlo M. Croce,et al. Causes and Consequences of MicroRNA Dysregulation , 2012, Cancer journal.
[88] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[89] J. Kirkwood,et al. Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients , 2012, Journal of Translational Medicine.
[90] Karen Sachs,et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators , 2012, Nature Biotechnology.
[91] R. Aebersold,et al. Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions , 2012, Nature Methods.
[92] R. Stallings,et al. Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers , 2012, Genome Biology.
[93] R. Iyengar,et al. Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. , 2012, Annual review of pharmacology and toxicology.
[94] Hugo Y. K. Lam,et al. Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.
[95] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[96] Pora Kim,et al. A High-Dimensional, Deep-Sequencing Study of Lung Adenocarcinoma in Female Never-Smokers , 2013, PloS one.
[97] Martin J. Aryee,et al. Epigenome-wide association data implicate DNA methylation as an intermediary of genetic risk in Rheumatoid Arthritis , 2013, Nature Biotechnology.
[98] E. Berg,et al. Building Predictive Models for Mechanism-of-Action Classification from Phenotypic Assay Data Sets , 2013, Journal of biomolecular screening.
[99] Manuel C. Peitsch,et al. A Modular Cell-Type Focused Inflammatory Process Network Model for Non-Diseased Pulmonary Tissue , 2013, Bioinformatics and biology insights.
[100] E. Berg,et al. Neoclassic Drug Discovery , 2013, Journal of biomolecular screening.
[101] M. Peng,et al. Toward a comprehensive characterization of a human cancer cell phosphoproteome. , 2013, Journal of proteome research.
[102] R. Gamelli,et al. Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013, Proceedings of the National Academy of Sciences.
[103] N. Perrimon,et al. Protein Complex–Based Analysis Framework for High-Throughput Data Sets , 2013, Science Signaling.
[104] David S. Wishart,et al. HMDB 3.0—The Human Metabolome Database in 2013 , 2012, Nucleic Acids Res..
[105] Sarah R. Langley,et al. Proteomics: from single molecules to biological pathways , 2012, Cardiovascular research.
[106] I. Tomlinson,et al. Whole-genome methylation analysis of benign and malignant colorectal tumours , 2013, The Journal of pathology.
[107] S. Carr,et al. Proteomic Mapping of Mitochondria in Living Cells via Spatially Restricted Enzymatic Tagging , 2013, Science.
[108] Peer Bork,et al. PTMcode: a database of known and predicted functional associations between post-translational modifications in proteins , 2012, Nucleic Acids Res..
[109] Benjamin Meder,et al. Alterations in cardiac DNA methylation in human dilated cardiomyopathy , 2013, EMBO molecular medicine.
[110] Ronan M. T. Fleming,et al. A community-driven global reconstruction of human metabolism , 2013, Nature Biotechnology.